Jefferies Financial Group set a €68.00 ($79.07) target price on Fresenius Medical Care AG & Co. KGaA (ETR:FME) in a report issued on Friday, June 28th, Borsen Zeitung reports. The brokerage currently has a neutral rating on the stock.
A number of other research analysts also recently commented on FME. JPMorgan Chase & Co. set a €56.70 ($65.93) target price on Fresenius SE & Co KGaA and gave the stock a buy rating in a report on Monday, June 24th. Kepler Capital Markets set a €80.00 ($93.02) target price on Fresenius Medical Care AG & Co. KGaA and gave the stock a buy rating in a report on Thursday, May 2nd. Berenberg Bank reduced their target price on from GBX 4,600 ($60.11) to GBX 3,800 ($49.65) and set a hold rating on the stock in a report on Friday, June 28th. HSBC set a €101.00 ($117.44) price target on Grenke and gave the stock a buy rating in a report on Thursday, April 25th. Finally, Independent Research set a €74.00 ($86.05) price target on Fresenius Medical Care AG & Co. KGaA and gave the stock a neutral rating in a report on Monday, June 17th. Seven equities research analysts have rated the stock with a hold rating and eleven have assigned a buy rating to the company’s stock. The company presently has a consensus rating of Buy and an average price target of €82.57 ($96.01).
ETR:FME traded down €0.74 ($0.86) during trading hours on Friday, reaching €67.00 ($77.91). 805,829 shares of the stock were exchanged, compared to its average volume of 704,197. The company has a quick ratio of 0.67, a current ratio of 1.02 and a debt-to-equity ratio of 100.05. The company’s 50 day moving average is €68.38. Fresenius Medical Care AG & Co. KGaA has a 52 week low of €55.44 ($64.47) and a 52 week high of €91.74 ($106.67). The firm has a market cap of $20.45 billion and a PE ratio of 10.43.
Fresenius Medical Care AG & Co KGaA, a kidney dialysis company, provides dialysis care and related services, and other health care services in Germany, the United States, and internationally. It offers dialysis treatment and related laboratory and diagnostic services through a network of outpatient dialysis clinics; materials, training, and patient support services comprising clinical monitoring, follow-up assistance, and arranging for delivery of the supplies to the patient's residence; and dialysis services under contract to hospitals in the United States for the hospitalized end-stage renal disease (ESRD) patients and for patients suffering from acute kidney failure.
Further Reading: Cost of Debt
Receive News & Ratings for Fresenius Medical Care AG & Co. KGaA Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Fresenius Medical Care AG & Co. KGaA and related companies with MarketBeat.com's FREE daily email newsletter.